Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0873 in patients with COPD
NCT00132730Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of MK-0873 in chronic obstructive pulmonary disease (COPD) (6 arms), sponsored by Merck & Co. Primary endpoint: Pre-dose (Trough) Forced Expiratory Volume in 1 Second at 12 weeks. Started Jun 2004; status: terminated.
02
Drugs
MK-0873
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00132730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132730.